Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ray Borrow

Showing results (11-20 of 403) with videos related to

Pageof 41
Sort By:
Human Vaccines & Immunotherapeutics|April 28, 2015
Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?Helen Findlow, Ray Borrow
Vaccine|June 5, 2007
Issues surrounding standardization of meningococcal group W135 serologyPaul Balmer, Ray Borrow
Methods in Molecular Medicine|September 6, 2003
Assessment of functional antibody responsesRay Borrow, Paul Balmer
Expert Review of Vaccines|March 3, 2009
Prevention of meningococcal serogroup C disease by NeisVac-CRay Borrow, Jamie Findlow
Microorganisms|October 31, 2020
Herd Protection against Meningococcal Disease through VaccinationStephen A Clark, Ray Borrow
Human Vaccines & Immunotherapeutics|April 30, 2020
Meningococcal infections among refugees and immigrants: silent threats of past, present and futureEner Cagri Dinleyici, Ray Borrow
Vaccine|March 10, 2005
Meningococcal surrogates of protection--serum bactericidal antibody activityRay Borrow, Paul Balmer, Elizabeth Miller
Travel Medicine and Infectious Disease|September 1, 2009
Serogroup B meningococcal disease during Hajj: preparing for the worst scenarioMohamed K M Khalil, Ray Borrow
Expert Opinion on Biological Therapy|May 28, 2011
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesiclesXilian Bai, Jamie Findlow, Ray Borrow
Clinical and Diagnostic Laboratory Immunology|September 11, 2003
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in EnglandNick Andrews, Ray Borrow, Elizabeth Miller
Pageof 41

Showing results (11-20 of 403) with videos related to

Sort By:
Pageof 41
Human Vaccines & Immunotherapeutics|April 28, 2015
Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?Helen Findlow, Ray Borrow
Vaccine|June 5, 2007
Issues surrounding standardization of meningococcal group W135 serologyPaul Balmer, Ray Borrow
Methods in Molecular Medicine|September 6, 2003
Assessment of functional antibody responsesRay Borrow, Paul Balmer
Expert Review of Vaccines|March 3, 2009
Prevention of meningococcal serogroup C disease by NeisVac-CRay Borrow, Jamie Findlow
Microorganisms|October 31, 2020
Herd Protection against Meningococcal Disease through VaccinationStephen A Clark, Ray Borrow
Human Vaccines & Immunotherapeutics|April 30, 2020
Meningococcal infections among refugees and immigrants: silent threats of past, present and futureEner Cagri Dinleyici, Ray Borrow
Vaccine|March 10, 2005
Meningococcal surrogates of protection--serum bactericidal antibody activityRay Borrow, Paul Balmer, Elizabeth Miller
Travel Medicine and Infectious Disease|September 1, 2009
Serogroup B meningococcal disease during Hajj: preparing for the worst scenarioMohamed K M Khalil, Ray Borrow
Expert Opinion on Biological Therapy|May 28, 2011
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesiclesXilian Bai, Jamie Findlow, Ray Borrow
Clinical and Diagnostic Laboratory Immunology|September 11, 2003
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in EnglandNick Andrews, Ray Borrow, Elizabeth Miller
Pageof 41